Skip to content

Author

K. Fidyt

We have 2 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.

It is demonstrated that overexpression of wild-type IKZF1, a tumor suppressor frequently mutated in high-risk BCP-ALL, upregulates CD20 and promotes leukemic B cell maturation, and the use of mTORC1 inhibitors to sensitize BCP-ALL cells to CD20-directed immunotherapies is supported.

Agnieszka Dąbkowska, Martyna Janowska, Agata Pastorczak et al. · 0 citations
Open access Aug 2026

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

It is shown that CAR structure is a critical determinant of CD19 loss in tumor B cells, and Mathematical modeling indicates that the failure of CD19-4-1BB-based CAR-T cells to eliminate CD19low cells, unlike CD28-based CARs, promotes the expansion of resistant populations.

Marta Krawczyk, K. Fidyt, Narcís Fernandez-Fuentes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.